Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.

Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2024 Jun; 30(6):584.e1-584.e13.

View in: PubMed

subject areas

Antigens, CD19
Biological Products
Humans
Immunotherapy, Adoptive
Lymphoma, Large B-Cell, Diffuse
Receptors, Antigen, T-Cell
Treatment Outcome

authors with profiles

Michael Bishop